Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
Status:
Withdrawn
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Approximately 225 patients meeting study entry requirements will be enrolled and randomized
(2:1, active versus placebo superimposed on background treatment) to R788 or placebo.
Patients will be followed for efficacy and safety parameters for 6 months. The investigator
should taper corticosteroids if clinically warranted.